EU CDK 4/6 Inhibitor Safety Info Update Goes Ahead
Product Info Warns Of Rare But Severe Pulmonary Side Effects
Executive Summary
The EU product information for Ibrance, Verzenios and Kisqali is being updated to include interstitial lung disease and pneumonitis. The change has already been implemented in the US.